Pd-Rx Pharmaceutical (PDRX) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of Pd-Rx Pharmaceutical $7.93, price $3.10, upside +155.8%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Pd-Rx Pharmaceutical for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $2.00 – $7.20 · fair‑value band $6.98 – $9.21 · the $3.10 price screens below the $7.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Pd-Rx Pharmaceutical in your weekly email
Every Wednesday you see whether Pd-Rx Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services.
Show more
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services. In addition, the company offers a dispensing platform, a manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a handling package; and PD-Rx Net, a web-based application designed to track prescriptions filled at the point of care and print prescription labels for prescriptions that are filled onsite. Further, it provides primary care, urgent care, pain management, occupational and orthopedic medicine, bariatric, dental, and other physician dispensing services. The company serves the governmental, commercial, and point-of-care pharmaceutical industry. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is based in Oklahoma City, Oklahoma.
Stock analysis
Pd-Rx Pharmaceutical (PDRX) currently trades at $3.10, while our model-based Fair Value estimate is $7.93, implying the stock looks roughly 60.9% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $9.38 per share, and 7 of the 7 models we run sit above the $3.10 price.
Bear case: the Asset-Based group reads lowest at $4.00, and 0 of the 7 models stay below the price. Evidence for this calculation is medium.
Scenario range: $6.98 (bear) to $9.21 (bull), the price of $3.10 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Pd-Rx Pharmaceutical reported revenue of $18.3M in FY2025 versus $21.6M in FY2021, a compound −4.0%/yr. Reported net income was −$258K in FY2025.
Key figures
Market cap $5.7M · P/E ratio 2.9 · P/S ratio 0.31 · EPS (TTM) $1.08 · Net margin −1.4% · Return on equity −2.5% · Return on assets (EBIT) 5.1% · Operating margin 2.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 156%, PDRX screens cheaper than that median.
Fair Value models
Bear $6.98Fair Value $7.93Bull $9.21
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($1.08 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−3.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.7%
Start year 2020 (pandemic). Over 10 years: −0.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.1% (2020) → −2.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside+156% · Top 25%
Profitability
Return on assets−2% · Bottom 25%
Net margin (TTM)−1% · Bottom 25%
Operating margin (TTM)2% · Below median
Growth and dividend
Revenue growth−3% · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pd-Rx Pharmaceutical Fair Value". https://www.fairvalue-calculator.com/stock/PDRX
Frequently asked questions
Is Pd-Rx Pharmaceutical (PDRX) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $7.93 versus the last price from Sep 18, 2026 of $3.10, about +156% upside (undervalued).
What is the fair value of PDRX?
Our model-based fair value for Pd-Rx Pharmaceutical is $7.93 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $3.10.
What is the quality score of PDRX?
Pd-Rx Pharmaceutical has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pd-Rx Pharmaceutical (PDRX)?
Our model-based price target is the fair value of $7.93 (as of Sep 24, 2026) from 7 valuation models. Cautious scenario $6.98, optimistic scenario $9.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Pd-Rx Pharmaceutical stock forecast for 2026?
Our models put fair value at $7.93, about +156% upside versus the last price from Sep 18, 2026 of $3.10 (undervalued). Cautious scenario $6.98, optimistic scenario $9.21. The calculation is refreshed regularly with new filings.
What is the revenue of Pd-Rx Pharmaceutical (PDRX)?
Pd-Rx Pharmaceutical reported trailing-twelve-month revenue of about $18.3M (latest available figure, as of Sep 24, 2026).
What growth is priced into Pd-Rx Pharmaceutical (PDRX)?
For today's price to be fair in a discounted-cash-flow model, Pd-Rx Pharmaceutical would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 12.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -2.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of PDRX use?
Our models discount Pd-Rx Pharmaceutical at 12.2 %: a base by market capitalisation (nano), damped by beta 1000000.00, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pd-Rx Pharmaceutical that is less than minus 40 % per year a year over ten years, using the same discount rate (12.2 %) and the same formula as our fair value.
How much growth has Pd-Rx Pharmaceutical (PDRX) delivered so far?
Over the past 5 years revenue at Pd-Rx Pharmaceutical grew -2.7 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pd-Rx Pharmaceutical (PDRX) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Pd-Rx Pharmaceutical (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pd-Rx Pharmaceutical (PDRX)?
The free-cash-flow yield on the price is 15.92 %: that much free cash flow Pd-Rx Pharmaceutical produces per unit of market value. When it exceeds the discount rate of our models (12.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pd-Rx Pharmaceutical (PDRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pd-Rx Pharmaceutical it is $7.93 per share (as of Sep 24, 2026), against a price of $3.10. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Pd-Rx Pharmaceutical stock overvalued or undervalued in 2026?
As of Sep 24, 2026, PDRX trades below its calculated fair value: price $3.10, fair value $7.93, a gap of about +156% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PDRX?
No. The price is what the market pays today ($3.10); the fair value is what the company's own numbers justify ($7.93). For Pd-Rx Pharmaceutical the two are $4.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pd-Rx Pharmaceutical worth?
The market values Pd-Rx Pharmaceutical at about $5.7M (market capitalisation, as of Sep 24, 2026). Per share that is $3.10; our models calculate a fair value of $7.93 per share.
What do the bullish and bearish scenarios say about PDRX?
Our models span a range for Pd-Rx Pharmaceutical: cautious scenario $6.98, base $7.93, optimistic $9.21 per share (as of Sep 24, 2026, price $3.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PDRX?
Pd-Rx Pharmaceutical trades at a price-to-earnings ratio of 2.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.93 is built from several models across several years. Other multiples: P/B 0.6, P/S 0.3.
How solid is the balance sheet of Pd-Rx Pharmaceutical (PDRX)?
Balance-sheet figures for Pd-Rx Pharmaceutical (as of Sep 24, 2026): return on equity −2.5%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is PDRX from its 52-week high?
Pd-Rx Pharmaceutical trades at $3.10, about 7% below its 52-week high of $3.35 and 13% above the low of $2.75 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $7.93 is for.
Which stocks are comparable to Pd-Rx Pharmaceutical?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pd-Rx Pharmaceutical stock attractive at the current price?
The data as of Sep 24, 2026: price $3.10, calculated fair value $7.93 (+156%), Quality Score 70/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PDRX calculated?
We run Pd-Rx Pharmaceutical through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $7.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Pd-Rx Pharmaceutical currently trades 156 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pd-Rx Pharmaceutical (PDRX)?
The latest price we hold is from Sep 18, 2026 and stands at $3.10. Our model-based fair value is $7.93, about +156% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pd-Rx Pharmaceutical right now?
The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($6.98). The market is more pessimistic than our downside scenario.
Key figures of Pd-Rx Pharmaceutical
How large is the market capitalisation of Pd-Rx Pharmaceutical (PDRX)?
The market capitalisation of Pd-Rx Pharmaceutical is $5.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pd-Rx Pharmaceutical (PDRX)?
The price-to-sales ratio of Pd-Rx Pharmaceutical is 0.31 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pd-Rx Pharmaceutical (PDRX)?
Earnings per share at Pd-Rx Pharmaceutical are $1.08 (price ÷ EPS = P/E 2.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pd-Rx Pharmaceutical (PDRX)?
The net margin of Pd-Rx Pharmaceutical is −1.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pd-Rx Pharmaceutical (PDRX)?
The return on equity (ROE) of Pd-Rx Pharmaceutical is −2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pd-Rx Pharmaceutical (PDRX)?
On an EBIT basis the return on assets of Pd-Rx Pharmaceutical is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pd-Rx Pharmaceutical (PDRX)?
The operating margin of Pd-Rx Pharmaceutical is 2.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pd-Rx Pharmaceutical (PDRX)?
Revenue at Pd-Rx Pharmaceutical is growing −2.5% versus a year earlier (3y avg −13.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pd-Rx Pharmaceutical (PDRX)?
Earnings per share at Pd-Rx Pharmaceutical are growing +60.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Pd-Rx Pharmaceutical (PDRX) hold?
Pd-Rx Pharmaceutical holds more cash than debt, $6.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Pd-Rx Pharmaceutical in the live analysis
One click puts Pd-Rx Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026